Mesalamine Tablet, Delayed Release
Product Images NDC 70771-1110

Product Visual Gallery

This gallery contains 1 technical images submitted to the FDA as part of the official labeling for Mesalamine (NDC 70771-1110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mesalamine Delayed-release Tablets Usp, 800 mg (F3177974 28c9 4318 Bfde Ff1cd0bd0d8a 02)

This is a description of Mesalamine Delayed-release Tablets, USP in a dosage of 800 mg. This medicine is used to treat moderately active ulcerative colitis. The recommended dosage is between 1.6 and 4.8 g daily, depending on the severity of the disease. There are 180 tablets in the package, and they should be swallowed whole, not chewed or broken. This medication should be stored at a temperature of 20°C to 25°C and protected from moisture. The manufacturer is Cadia Healthcare Ltd, located in India. Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.